Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 137

1.

Performance evaluation of 3 serodiagnostic peptide epitopes and the derived multi-epitope peptide OvNMP-48 for detection of Onchocerca volvulus infection.

Lagatie O, Verheyen A, Nijs E, Batsa Debrah L, Debrah YA, Stuyver LJ.

Parasitol Res. 2019 Jul;118(7):2263-2270. doi: 10.1007/s00436-019-06345-3. Epub 2019 May 14.

2.

Patent infections with soil-transmitted helminths and Schistosoma mansoni are not associated with increased prevalence of antibodies to the Onchocerca volvulus peptide epitopes OvMP-1 and OvMP-23.

Vlaminck J, Lagatie O, Verheyen A, Dana D, Van Dorst B, Mekonnen Z, Levecke B, Stuyver LJ.

Parasit Vectors. 2019 Jan 28;12(1):63. doi: 10.1186/s13071-019-3308-z.

3.

Linear epitopes in Onchocerca volvulus vaccine candidate proteins and excretory-secretory proteins.

Lagatie O, Verheyen A, Van Dorst B, Batsa Debrah L, Debrah A, Stuyver LJ.

Parasite Immunol. 2018 Nov;40(11):e12587. doi: 10.1111/pim.12587. Epub 2018 Oct 8.

4.

Proof-of-Concept Rapid Diagnostic Test for Onchocerciasis: Exploring Peptide Biomarkers and the Use of Gold Nanoshells as Reporter Nanoparticles.

Gonzalez-Moa MJ, Van Dorst B, Lagatie O, Verheyen A, Stuyver L, Biamonte MA.

ACS Infect Dis. 2018 Jun 8;4(6):912-917. doi: 10.1021/acsinfecdis.8b00031. Epub 2018 Mar 21.

5.

Droplet digital PCR is an accurate method to assess methylation status on FFPE samples.

Van Wesenbeeck L, Janssens L, Meeuws H, Lagatie O, Stuyver L.

Epigenetics. 2018;13(3):207-213. doi: 10.1080/15592294.2018.1448679. Epub 2018 Apr 18.

6.

Diagnostic tools for soil-transmitted helminths control and elimination programs: A pathway for diagnostic product development.

Lim MD, Brooker SJ, Belizario VY Jr, Gay-Andrieu F, Gilleard J, Levecke B, van Lieshout L, Medley GF, Mekonnen Z, Mirams G, Njenga SM, Odiere MR, Rudge JW, Stuyver L, Vercruysse J, Vlaminck J, Walson JL; Annecy STH diagnostic experts group.

PLoS Negl Trop Dis. 2018 Mar 1;12(3):e0006213. doi: 10.1371/journal.pntd.0006213. eCollection 2018 Mar. No abstract available.

7.

Evaluation of the Diagnostic Performance of Onchocerca volvulus Linear Epitopes in a Peptide Enzyme-Linked Immunosorbent Assay.

Lagatie O, Verheyen A, Nijs E, Van Dorst B, Batsa Debrah L, Debrah A, Supali T, Sartono E, Stuyver LJ.

Am J Trop Med Hyg. 2018 Mar;98(3):779-785. doi: 10.4269/ajtmh.17-0756. Epub 2018 Jan 4.

8.

2-methyl butyramide, a previously identified urine biomarker for Ascaris lumbricoides, is not present in infected Indonesian individuals.

Lagatie O, Njumbe Ediage E, Pikkemaat JA, Djuardi Y, Stuyver LJ.

Parasit Vectors. 2017 Dec 29;10(1):629. doi: 10.1186/s13071-017-2600-z.

9.

Sampling and detection of airborne influenza virus towards point-of-care applications.

Ladhani L, Pardon G, Meeuws H, van Wesenbeeck L, Schmidt K, Stuyver L, van der Wijngaart W.

PLoS One. 2017 Mar 28;12(3):e0174314. doi: 10.1371/journal.pone.0174314. eCollection 2017.

10.

Identification of three immunodominant motifs with atypical isotype profile scattered over the Onchocerca volvulus proteome.

Lagatie O, Van Dorst B, Stuyver LJ.

PLoS Negl Trop Dis. 2017 Jan 26;11(1):e0005330. doi: 10.1371/journal.pntd.0005330. eCollection 2017 Jan.

11.

Plasma-derived parasitic microRNAs have insufficient concentrations to be used as diagnostic biomarker for detection of Onchocerca volvulus infection or treatment monitoring using LNA-based RT-qPCR.

Lagatie O, Batsa Debrah L, Debrah A, Stuyver LJ.

Parasitol Res. 2017 Mar;116(3):1013-1022. doi: 10.1007/s00436-017-5382-5. Epub 2017 Jan 22.

12.

An isothermal DNA amplification method for detection of Onchocerca volvulus infection in skin biopsies.

Lagatie O, Merino M, Batsa Debrah L, Debrah AY, Stuyver LJ.

Parasit Vectors. 2016 Dec 1;9(1):624.

13.

Bioassay Development for Ultrasensitive Detection of Influenza A Nucleoprotein Using Digital ELISA.

Leirs K, Tewari Kumar P, Decrop D, Pérez-Ruiz E, Leblebici P, Van Kelst B, Compernolle G, Meeuws H, Van Wesenbeeck L, Lagatie O, Stuyver L, Gils A, Lammertyn J, Spasic D.

Anal Chem. 2016 Sep 6;88(17):8450-8. doi: 10.1021/acs.analchem.6b00502. Epub 2016 Aug 15.

PMID:
27487722
14.

Evaluation of the diagnostic potential of urinary N-Acetyltyramine-O,β-glucuronide (NATOG) as diagnostic biomarker for Onchocerca volvulus infection.

Lagatie O, Njumbe Ediage E, Batsa Debrah L, Diels L, Nolten C, Vinken P, Debrah A, Dillen L, Silber S, Stuyver LJ.

Parasit Vectors. 2016 May 23;9(1):302. doi: 10.1186/s13071-016-1582-6.

15.

A Downward Trend of the Ratio of Influenza RNA Copy Number to Infectious Viral Titer in Hospitalized Influenza A-Infected Patients.

Van Wesenbeeck L, D'Haese D, Tolboom J, Meeuws H, Dwyer DE, Holmes M, Ison MG, Katz K, McGeer A, Sadoff J, Weverling GJ, Stuyver L.

Open Forum Infect Dis. 2015 Nov 3;2(4):ofv166. doi: 10.1093/ofid/ofv166. eCollection 2015 Dec.

16.

Integration of an optical CMOS sensor with a microfluidic channel allows a sensitive readout for biological assays in point-of-care tests.

Van Dorst B, Brivio M, Van Der Sar E, Blom M, Reuvekamp S, Tanzi S, Groenhuis R, Adojutelegan A, Lous EJ, Frederix F, Stuyver LJ.

Biosens Bioelectron. 2016 Apr 15;78:126-131. doi: 10.1016/j.bios.2015.11.027. Epub 2015 Nov 11.

PMID:
26599482
17.

Characterization of Rabbit Antibodies Against the Immunogenic JC Polyomavirus Peptide JCPyV_VP2_167-15mer.

Lagatie O, Tritsmans L, Stuyver LJ.

Viral Immunol. 2015 Sep;28(7):405-9. doi: 10.1089/vim.2015.0010. Epub 2015 Jun 15.

PMID:
26075335
18.

Sampling variability between two mid-turbinate swabs of the same patient has implications for influenza viral load monitoring.

Van Wesenbeeck L, Meeuws H, D'Haese D, Ispas G, Houspie L, Van Ranst M, Stuyver LJ.

Virol J. 2014 Dec 24;11:233. doi: 10.1186/s12985-014-0233-9.

19.

JC virus quasispecies analysis reveals a complex viral population underlying progressive multifocal leukoencephalopathy and supports viral dissemination via the hematogenous route.

Van Loy T, Thys K, Ryschkewitsch C, Lagatie O, Monaco MC, Major EO, Tritsmans L, Stuyver LJ.

J Virol. 2015 Jan 15;89(2):1340-7. doi: 10.1128/JVI.02565-14. Epub 2014 Nov 12.

20.

Antibodies reacting with JCPyV_VP2 _167-15mer as a novel serological marker for JC polyomavirus infection.

Lagatie O, Van Loy T, Tritsmans L, Stuyver LJ.

Virol J. 2014 Oct 1;11:174. doi: 10.1186/1743-422X-11-174.

21.

Viral miRNAs in plasma and urine divulge JC polyomavirus infection.

Lagatie O, Van Loy T, Tritsmans L, Stuyver LJ.

Virol J. 2014 Sep 2;11:158. doi: 10.1186/1743-422X-11-158.

22.

Integration of clinical point-of-care requirements in a DNA microarray genotyping test.

Van Dorst B, Cremers A, Jans K, Van Domburg T, Steegen K, Huang C, Dorrer C, Lagae L, Ferwerda G, Stuyver LJ.

Biosens Bioelectron. 2014 Nov 15;61:605-11. doi: 10.1016/j.bios.2014.05.071. Epub 2014 Jun 11.

PMID:
24967749
23.

Circulating human microRNAs are not linked to JC polyomavirus serology or urinary viral load in healthy subjects.

Lagatie O, Van Loy T, Tritsmans L, Stuyver LJ.

Virol J. 2014 Mar 3;11:41. doi: 10.1186/1743-422X-11-41.

24.

Evaluation of an affordable HIV-1 virological failure assay and antiretroviral drug resistance genotyping protocol.

Bronze M, Aitken SC, Wallis CL, Steegen K, Stuyver LJ, de Wit TF, Stevens W.

J Virol Methods. 2013 Dec;194(1-2):300-7. doi: 10.1016/j.jviromet.2013.08.015. Epub 2013 Aug 28.

PMID:
23994150
25.

The miRNA world of polyomaviruses.

Lagatie O, Tritsmans L, Stuyver LJ.

Virol J. 2013 Aug 28;10:268. doi: 10.1186/1743-422X-10-268. Review.

26.

Quasispecies analysis of JC virus DNA present in urine of healthy subjects.

Van Loy T, Thys K, Tritsmans L, Stuyver LJ.

PLoS One. 2013 Aug 15;8(8):e70950. doi: 10.1371/journal.pone.0070950. eCollection 2013.

27.

Targeted resequencing of HIV variants by microarray thermodynamics.

Hadiwikarta WW, Van Dorst B, Hollanders K, Stuyver L, Carlon E, Hooyberghs J.

Nucleic Acids Res. 2013 Oct;41(18):e173. doi: 10.1093/nar/gkt682. Epub 2013 Aug 8.

28.

Sensitive assessment of the virologic outcomes of stopping and restarting non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy.

Geretti AM, Fox Z, Johnson JA, Booth C, Lipscomb J, Stuyver LJ, Tachedjian G, Baxter J, Touloumi G, Lehmann C, Owen A, Phillips A; INSIGHT Strategies for Management of Antiretroviral Therapy (SMART) Study Group.

PLoS One. 2013 Jul 18;8(7):e69266. doi: 10.1371/journal.pone.0069266. Print 2013.

29.

Comparison of the FilmArray RP, Verigene RV+, and Prodesse ProFLU+/FAST+ multiplex platforms for detection of influenza viruses in clinical samples from the 2011-2012 influenza season in Belgium.

Van Wesenbeeck L, Meeuws H, Van Immerseel A, Ispas G, Schmidt K, Houspie L, Van Ranst M, Stuyver L.

J Clin Microbiol. 2013 Sep;51(9):2977-85. doi: 10.1128/JCM.00911-13. Epub 2013 Jul 3.

30.

Amplification and sequencing of the hepatitis C virus NS3/4A protease and the NS5B polymerase regions for genotypic resistance detection of clinical isolates of subtypes 1a and 1b.

Koletzki D, Pattery T, Fevery B, Vanhooren L, Stuyver LJ.

Methods Mol Biol. 2013;1030:137-49. doi: 10.1007/978-1-62703-484-5_12.

PMID:
23821266
31.

An antibody response to human polyomavirus 15-mer peptides is highly abundant in healthy human subjects.

Stuyver LJ, Verbeke T, Van Loy T, Van Gulck E, Tritsmans L.

Virol J. 2013 Jun 12;10:192. doi: 10.1186/1743-422X-10-192.

32.

Evaluation of a proximity extension assay for the detection of H1 2009 pandemic influenza viruses.

Van Wesenbeeck L, Meeuws H, De Wolf H, Stuyver L.

J Virol Methods. 2013 Oct;193(1):77-84. doi: 10.1016/j.jviromet.2013.05.008. Epub 2013 May 23.

PMID:
23707923
33.

A pragmatic approach to HIV-1 drug resistance determination in resource-limited settings by use of a novel genotyping assay targeting the reverse transcriptase-encoding region only.

Aitken SC, Bronze M, Wallis CL, Stuyver L, Steegen K, Balinda S, Kityo C, Stevens W, Rinke de Wit TF, Schuurman R.

J Clin Microbiol. 2013 Jun;51(6):1757-61. doi: 10.1128/JCM.00118-13. Epub 2013 Mar 27.

34.

A label-free potentiometric sensor principle for the detection of antibody-antigen interactions.

Ozdemir MS, Marczak M, Bohets H, Bonroy K, Roymans D, Stuyver L, Vanhoutte K, Pawlak M, Bakker E.

Anal Chem. 2013 May 7;85(9):4770-6. doi: 10.1021/ac400514u. Epub 2013 Apr 16.

PMID:
23534536
35.

HIV-1 phenotypic reverse transcriptase inhibitor drug resistance test interpretation is not dependent on the subtype of the virus backbone.

Bronze M, Steegen K, Wallis CL, De Wolf H, Papathanasopoulos MA, Van Houtte M, Stevens WS, de Wit TR, Stuyver LJ; ART-A Consortium.

PLoS One. 2012;7(4):e34708. doi: 10.1371/journal.pone.0034708. Epub 2012 Apr 9.

36.

Ultra-deep sequencing of HIV-1 reverse transcriptase before start of an NNRTI-based regimen in treatment-naive patients.

Messiaen P, Verhofstede C, Vandenbroucke I, Dinakis S, Van Eygen V, Thys K, Winters B, Aerssens J, Vogelaers D, Stuyver LJ, Vandekerckhove L.

Virology. 2012 Apr 25;426(1):7-11. doi: 10.1016/j.virol.2012.01.002. Epub 2012 Feb 4.

37.

Study of genotypic and phenotypic HIV-1 dynamics of integrase mutations during raltegravir treatment: a refined analysis by ultra-deep 454 pyrosequencing.

Armenia D, Vandenbroucke I, Fabeni L, Van Marck H, Cento V, D'Arrigo R, Van Wesenbeeck L, Scopelliti F, Micheli V, Bruzzone B, Lo Caputo S, Aerssens J, Rizzardini G, Tozzi V, Narciso P, Antinori A, Stuyver L, Perno CF, Ceccherini-Silberstein F.

J Infect Dis. 2012 Feb 15;205(4):557-67. doi: 10.1093/infdis/jir821. Epub 2012 Jan 11.

38.

A synthetic HIV-1 subtype C backbone generates comparable PR and RT resistance profiles to a subtype B backbone in a recombinant virus assay.

Nauwelaers D, Van Houtte M, Winters B, Steegen K, Van Baelen K, Chi E, Zhou M, Steiner D, Bonesteel R, Aston C, Stuyver LJ.

PLoS One. 2011;6(5):e19643. doi: 10.1371/journal.pone.0019643. Epub 2011 May 24.

39.

HIV-1 dual/mixed tropic isolates show different genetic and phenotypic characteristics and response to maraviroc in vitro.

Svicher V, Balestra E, Cento V, Sarmati L, Dori L, Vandenbroucke I, D'Arrigo R, Buonomini AR, Van Marck H, Surdo M, Saccomandi P, Mostmans W, Aerssens J, Aquaro S, Stuyver LJ, Andreoni M, Ceccherini-Silberstein F, Perno CF.

Antiviral Res. 2011 Apr;90(1):42-53. doi: 10.1016/j.antiviral.2011.02.005. Epub 2011 Feb 22.

PMID:
21349294
40.

Sequence and phenotypic analysis for resistance monitoring in hepatitis C virus drug development: recommendations from the HCV DRAG.

Kwong AD, Najera I, Bechtel J, Bowden S, Fitzgibbon J, Harrington P, Kempf D, Kieffer TL, Koletzki D, Kukolj G, Lim S, Pilot-Matias T, Lin K, Mani N, Mo H, O'Rear J, Otto M, Parkin N, Pawlotsky JM, Petropoulos C, Picchio G, Ralston R, Reeves JD, Schooley RT, Seiwert S, Standring D, Stuyver L, Sullivan J, Miller V; Forum for Collaborative Human Immunodeficiency Virus Research; HCV Drug Development Advisory Group (HCV DRAG); Sequence Analysis Working Group (SAWG); Phenotype Analysis Working Group (PAWG).

Gastroenterology. 2011 Mar;140(3):755-60. doi: 10.1053/j.gastro.2011.01.029. Epub 2011 Jan 19. No abstract available.

PMID:
21255574
41.

Comparison of phenotypic and genotypic tropism determination in triple-class-experienced HIV patients eligible for maraviroc treatment.

Vandekerckhove L, Verhofstede C, Demecheleer E, De Wit S, Florence E, Fransen K, Moutschen M, Mostmans W, Kabeya K, Mackie N, Plum J, Vaira D, Van Baelen K, Vandenbroucke I, Van Eygen V, Van Marck H, Vogelaers D, Geretti AM, Stuyver LJ.

J Antimicrob Chemother. 2011 Feb;66(2):265-72. doi: 10.1093/jac/dkq458. Epub 2010 Dec 31.

42.

Cross-resistance profile determination of two second-generation HIV-1 integrase inhibitors using a panel of recombinant viruses derived from raltegravir-treated clinical isolates.

Van Wesenbeeck L, Rondelez E, Feyaerts M, Verheyen A, Van der Borght K, Smits V, Cleybergh C, De Wolf H, Van Baelen K, Stuyver LJ.

Antimicrob Agents Chemother. 2011 Jan;55(1):321-5. doi: 10.1128/AAC.01733-09. Epub 2010 Oct 18.

43.

A comparative analysis of HIV drug resistance interpretation based on short reverse transcriptase sequences versus full sequences.

Steegen K, Bronze M, Van Craenenbroeck E, Winters B, Van der Borght K, Wallis CL, Stevens W, Rinke de Wit TF, Stuyver LJ; ART-A consortium.

AIDS Res Ther. 2010 Oct 15;7:38. doi: 10.1186/1742-6405-7-38.

44.

HIV-1 V3 envelope deep sequencing for clinical plasma specimens failing in phenotypic tropism assays.

Vandenbroucke I, Van Marck H, Mostmans W, Van Eygen V, Rondelez E, Thys K, Van Baelen K, Fransen K, Vaira D, Kabeya K, De Wit S, Florence E, Moutschen M, Vandekerckhove L, Verhofstede C, Stuyver LJ.

AIDS Res Ther. 2010 Feb 15;7:4. doi: 10.1186/1742-6405-7-4.

45.

Mutation Q95K enhances N155H-mediated integrase inhibitor resistance and improves viral replication capacity.

Fun A, Van Baelen K, van Lelyveld SF, Schipper PJ, Stuyver LJ, Wensing AM, Nijhuis M.

J Antimicrob Chemother. 2010 Nov;65(11):2300-4. doi: 10.1093/jac/dkq319. Epub 2010 Aug 24.

PMID:
20736234
46.

Development and evaluation of an automated hepatitis C virus NS5B sequence-based subtyping assay.

Koletzki D, Dumont S, Vermeiren H, Fevery B, De Smet P, Stuyver LJ.

Clin Chem Lab Med. 2010 Aug;48(8):1095-102. doi: 10.1515/CCLM.2010.236.

PMID:
20578969
47.

Secondary integrase resistance mutations found in HIV-1 minority quasispecies in integrase therapy-naive patients have little or no effect on susceptibility to integrase inhibitors.

Ceccherini-Silberstein F, Van Baelen K, Armenia D, Trignetti M, Rondelez E, Fabeni L, Scopelliti F, Pollicita M, Van Wesenbeeck L, Van Eygen V, Dori L, Sarmati L, Aquaro S, Palamara G, Andreoni M, Stuyver LJ, Perno CF.

Antimicrob Agents Chemother. 2010 Sep;54(9):3938-48. doi: 10.1128/AAC.01720-09. Epub 2010 May 17.

48.

The HIV-1 integrase mutations Y143C/R are an alternative pathway for resistance to Raltegravir and impact the enzyme functions.

Reigadas S, Anies G, Masquelier B, Calmels C, Stuyver LJ, Parissi V, Fleury H, Andreola ML.

PLoS One. 2010 Apr 26;5(4):e10311. doi: 10.1371/journal.pone.0010311.

49.

Development of a real-time multiplex RSV detection assay for difficult respiratory samples, using ultrasone waves and MNAzyme technology.

Nauwelaers D, Vijgen L, Atkinson C, Todd A, Geretti AM, Van Ranst M, Stuyver L.

J Clin Virol. 2009 Nov;46(3):238-43. doi: 10.1016/j.jcv.2009.08.013. Epub 2009 Sep 15.

PMID:
19758841
50.

A combined genotypic and phenotypic human immunodeficiency virus type 1 recombinant virus assay for the reverse transcriptase and integrase genes.

Van Baelen K, Rondelez E, Van Eygen V, Ariën K, Clynhens M, Van den Zegel P, Winters B, Stuyver LJ.

J Virol Methods. 2009 Nov;161(2):231-9. doi: 10.1016/j.jviromet.2009.06.015. Epub 2009 Jun 25.

PMID:
19559730

Supplemental Content

Loading ...
Support Center